Clark Robin D, Ray Nicholas C, Williams Karen, Blaney Paul, Ward Stuart, Crackett Peter H, Hurley Christopher, Dyke Hazel J, Clark David E, Lockey Peter, Devos Rene, Wong Melanie, Porres Soraya S, Bright Colin P, Jenkins Robert E, Belanoff Joseph
Corcept Therapeutics, 149 Commonwealth Avenue, Menlo Park, CA 94025, USA.
Bioorg Med Chem Lett. 2008 Feb 15;18(4):1312-7. doi: 10.1016/j.bmcl.2008.01.027. Epub 2008 Jan 11.
Addition of the 4-fluorophenylpyrazole group to the previously described 2-azadecalin glucocorticoid receptor (GR) antagonist 1 resulted in significantly enhanced functional activity. SAR of the bridgehead substituent indicated that whereas groups as small as methyl afforded high GR binding, GR functional activity was enhanced by larger groups such as benzyl, substituted ethers, and aminoalkyl derivatives. GR antagonists with binding and functional activity comparable to mifepristone were discovered (e.g., 52: GR binding K(i) 0.7 nM; GR reporter gene functional K(i) 0.6 nM) and found to be highly selective over other steroid receptors. Analogues 43 and 45 had >50% oral bioavailability in the dog.
在先前描述的2-氮杂十氢化萘糖皮质激素受体(GR)拮抗剂1上添加4-氟苯基吡唑基团,导致功能活性显著增强。桥头取代基的构效关系表明,尽管甲基等小基团具有较高的GR结合能力,但苄基、取代醚和氨基烷基衍生物等较大基团可增强GR功能活性。发现了与米非司酮具有相当结合和功能活性的GR拮抗剂(例如,52:GR结合K(i) 0.7 nM;GR报告基因功能K(i) 0.6 nM),并发现其对其他类固醇受体具有高度选择性。类似物43和45在犬体内具有>50%的口服生物利用度。